Neurocrine Biosciences (NASDAQ:NBIX) Given New $182.00 Price Target at Morgan Stanley

Neurocrine Biosciences (NASDAQ:NBIX) had its target price decreased by stock analysts at Morgan Stanley from $196.00 to $182.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Morgan Stanley’s target price suggests a potential upside of 19.41% from the stock’s previous close.

NBIX has been the subject of several other reports. The Goldman Sachs Group started coverage on Neurocrine Biosciences in a research report on Tuesday, June 2nd. They issued a “buy” rating and a $213.00 target price for the company. Weiss Ratings cut shares of Neurocrine Biosciences from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday. Zacks Research lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 4th. Wedbush lifted their price objective on shares of Neurocrine Biosciences from $185.00 to $194.00 and gave the company an “outperform” rating in a report on Monday, August 3rd. Finally, Guggenheim upped their target price on shares of Neurocrine Biosciences from $200.00 to $222.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $200.86.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX traded down $4.07 during trading on Thursday, reaching $152.42. The stock had a trading volume of 602,944 shares, compared to its average volume of 1,204,314. The company has a market cap of $15.49 billion, a P/E ratio of 22.36, a PEG ratio of 0.57 and a beta of 0.39. Neurocrine Biosciences has a fifty-two week low of $122.14 and a fifty-two week high of $186.12. The business’s 50-day moving average price is $168.54 and its 200-day moving average price is $148.10.

Insider Buying and Selling

In other news, insider Ingrid Delaet sold 4,367 shares of Neurocrine Biosciences stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $181.02, for a total value of $790,514.34. Following the completion of the transaction, the insider owned 16,225 shares in the company, valued at approximately $2,937,049.50. This trade represents a 21.21% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Darin Lippoldt sold 10,000 shares of the business’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $179.60, for a total value of $1,796,000.00. Following the transaction, the insider directly owned 54,729 shares of the company’s stock, valued at approximately $9,829,328.40. This represents a 15.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 391,612 shares of company stock worth $61,858,105 over the last 90 days. 4.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in shares of Neurocrine Biosciences during the 2nd quarter worth $2,310,886,000. AQR Capital Management LLC increased its holdings in Neurocrine Biosciences by 18.0% in the fourth quarter. AQR Capital Management LLC now owns 3,271,706 shares of the company’s stock valued at $462,652,000 after buying an additional 498,058 shares during the last quarter. Renaissance Technologies LLC raised its stake in Neurocrine Biosciences by 8.0% in the first quarter. Renaissance Technologies LLC now owns 2,418,897 shares of the company’s stock valued at $318,665,000 after buying an additional 180,100 shares in the last quarter. Geode Capital Management LLC raised its stake in Neurocrine Biosciences by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 2,059,282 shares of the company’s stock valued at $291,342,000 after buying an additional 34,457 shares in the last quarter. Finally, Los Angeles Capital Management LLC lifted its holdings in Neurocrine Biosciences by 7.4% during the 4th quarter. Los Angeles Capital Management LLC now owns 1,291,278 shares of the company’s stock worth $178,248,000 after buying an additional 88,522 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Key Stories Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Positive INGREZZA data: Results from the KINECT-PRO Phase 4 study showed sustained improvements in quality of life, daily functioning and tardive dyskinesia movement severity. About 58% of patients reached the study’s threshold for symptomatic remission at Week 24, supporting INGREZZA’s commercial durability. KINECT-PRO study results
• Positive Sentiment: Analysts remain constructive: Neurocrine received an average “Moderate Buy” recommendation. Recent analyst price targets include $185 from JPMorgan, $191 from RBC and $213 from Goldman Sachs, indicating that many analysts still see upside based on the company’s growth outlook. Analyst recommendation
• Neutral Sentiment: Strong operating momentum but higher costs: Second-quarter revenue increased 39% year over year to $959 million, and 2026 INGREZZA sales guidance was raised to $2.825 billion–$2.875 billion. However, higher research and selling expenses, lower cash balances and acquisition-related financing are increasing investor scrutiny of margins, integration and capital allocation. NBIX stock analysis
• Negative Sentiment: Vykat XR safety concerns are weighing on sentiment: Prader-Willi syndrome experts cited serious adverse events associated with the drug, prompting renewed warnings following the Soleno acquisition. Investors may be concerned about regulatory scrutiny, adoption, potential liability and the financial return from the deal. Vykat XR safety concerns

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.